文献速递乳腺癌头颈与中枢神经肿瘤

HER-2低表达非Ⅳ期乳腺癌系统治疗后脑转移风险分层评估

[Risk stratification assessment of brain metastasis in newly diagnosed non-stage IV breast cancer patients with HER-2-low expression following systemic therapy].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

该回顾性研究纳入247例初诊非Ⅳ期HER-2低表达乳腺癌患者,中位随访51个月,138例出现脑转移。多因素分析确定ER阴性、组织分级Ⅱ/Ⅲ级、T2-T4期、N3、CA125和CA153高于参考值为独立风险因素,并据此将患者分为低、中、高和极高危组,各组脑转移发生率分别为0、33.33%、74.55%和100.00%。

要点

  • ER阴性、组织分级Ⅱ/Ⅲ级、T2-T4期、N3、CA125和CA153升高是脑转移独立风险因素。
  • 基于独立风险因素数目分层,低、中、高、极高危组脑转移发生率分别为0、33.33%、74.55%和100.00%。
  • 该分层有助于识别高脑转移风险患者并制定针对性随访策略。

核心结论

  • 基于临床病理特征和肿瘤标志物水平的脑转移风险分层有助于预测HER-2低表达非Ⅳ期乳腺癌患者系统治疗后的脑转移风险。

研究设计与样本

  • 回顾性分析2012年1月至2020年1月山东第一医科大学附属肿瘤医院收治的247例术后病理证实为HER-2低表达的非Ⅳ期乳腺癌患者,中位随访51个月。

主要发现

  • 138例患者随访中出现脑转移,脑转移发生中位时间为55.5个月。
  • 多因素分析显示ER阴性(OR=2.486,95%CI:1.117-5.533)、组织分级Ⅱ级(OR=12.175,95%CI:2.991-49.567)、组织分级Ⅲ级(OR=14.03,95%CI:3.383-58.184)、T2期(OR=2.272,95%CI:1.122-4.602)、T3期(OR=9.05,95%CI:1.804-45.398)、T4期(OR=6.691,95%CI:1.814-24.676)、N3(OR=2.748,95%CI:1.041-7.260)、CA125高于参考值(OR=3.933,95%CI:1.601-9.66)和CA153高于参考值(OR=2.578,95%CI:1.161-5.724)是脑转移的独立风险因素(P<0.05)。

关键数值与推荐

  • 0个风险因素为低危组,1-2个为中危组,3-4个为高危组,5-6个为极高危组。
  • 各组脑转移发生率分别为0(0/3)、33.33%(39/117)、74.55%(82/110)和100.00%(17/17)。

临床怎么用

  • 可根据独立风险因素数目对HER-2低表达非Ⅳ期乳腺癌患者进行脑转移风险分层,识别高危患者并制定针对性随访策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the independent risk factors of brain metastasis after systematic treatment in newly diagnosed non-stage Ⅳ breast cancer patients with HER-2-low expression, and to determine the recurrence risk stratification of brain metastasis, so as to guide the follow-up pattern of patients with different risk stratification. Methods: A retrospective analysis was performed on non-stage Ⅳ breast cancer patients admitted to Shandong First Medical University Affiliated Tumor Hospital from January 2012 to January 2020 with complete follow-up data. According to the immunohistochemical test results, only HER-2-low breast cancer patients confirmed by postoperative pathology were enrolled. The independent risk factors and the rate of brain metastasis were analyzed, and brain metastasis risk stratification was performed based on the number of independent risk factors. Results: 247 patients were enrolled, with a median follow-up of 51 months, 138 patients developed brain metastasis during follow-up, and the median development time was 55.5 months. Univariate analysis showed that age, menopause status, ER, tissue grade, T stage, N stage, CEA, CA125 and CA153 were associated with brain metastasis (P<0.05). Multivariate logistic regression analysis showed that negative ER (OR=2.486, 95% CI: 1.117-5.533), tissue gradeⅡ (OR=12.175, 95% CI: 2.991-49.567), tissue grade Ⅲ (OR=14.03, 95% CI: 3.383-58.184), T2 stage (OR=2.272, 95% CI: 1.122-4.602), T3 stage (OR=9.05, 95% CI: 1.804-45.398), T4 stage (OR=6.691, 95% CI: 1.814-24.676), number of axillary lymph node metastasis≥10, N3 (OR=2.748, 95% CI: 1.041-7.260), CA125 higher than the reference value (OR=3.933, 95% CI: 1.601-9.66) and CA153 higher than the reference value (OR=2.578, 95% CI: 1.161-5.724) were independent risk factors for brain metastasis (P<0.05). The risk of brain metastasis was assessed according to the number of independent risk factors in patients: Those with 0 risk factor were classified as low-risk group, 1-2 risk factors as medium-risk group, 3-4 risk factors as high-risk group, and 5-6 risk factors as extremely high-risk group. The incidence of brain metastases in each group were 0 (0/3), 33.33% (39/117), 74.55% (82/110) and 100.00% (17/17), respectively. Conclusion: The risk stratification of brain metastasis based on clinicopathological characteristics and levels of related tumor markers are helpful to predict the risk of brain metastasis in non-stage Ⅳ breast cancer patients with HER-2 low expression after systematic treatment, so as to accurately identify patients with high recurrence risk and formulate targeted follow-up strategies for them. 目的: 探讨初诊非Ⅳ期人表皮生长因子受体2(HER-2)低表达乳腺癌患者接受系统治疗后脑转移的独立风险因素,明确脑转移的复发风险分层,以指导不同风险分层患者的随诊。 方法: 回顾性分析2012年1月至2020年1月山东第一医科大学附属肿瘤医院收治的随访资料完整的非Ⅳ期乳腺癌患者,根据免疫组织化学检测结果,入组术后病理证实为HER-2低表达的乳腺癌患者,分析脑转移率,采用Logistic回归模型分析脑转移的独立风险因素,基于独立风险因素数目进行脑转移风险分层。 结果: 共入组247例患者,中位随访51个月,138例患者随访中出现脑转移,脑转移发生中位时间为55.5个月。单因素分析显示,脑转移与患者年龄、绝经状态、雌激素受体(ER)、组织分级、T分期、N分期、癌胚抗原、糖类抗原125(CA125)、CA153有关(P<0.05)。多因素分析显示,ER阴性(OR=2.486,95% CI:1.117~5.533)、组织分级Ⅱ级(OR=12.175,95% CI:2.991~49.567)、组织分级Ⅲ级(OR=14.03,95% CI:3.383~58.184)、T2期(OR=2.272,95% CI:1.122~4.602)、T3期(OR=9.05,95% CI:1.804~45.398)、T4期(OR=6.691,95% CI:1.814~24.676)、腋窝淋巴结转移数目≥10枚即N3期(OR=2.748,95% CI:1.041~7.260)、CA125高于参考值(OR=3.933,95% CI:1.601~9.660)以及CA153高于参考值(OR=2.578,95% CI:1.161~5.724)是脑转移的独立风险因素(均P<0.05)。按照患者存在独立风险因素个数进行脑转移风险评估,将具有0个风险因素者归为低危组,1~2个风险因素者归为中危组,3~4个风险因素者归为高危组,5~6个风险因素者归为极高危组,各组的脑转移发生率分别为0(0/3)、33.33%(39/117)、74.55%(82/110)和100.00%(17/17)。 结论: 根据临床病理特征及相关肿瘤标志物水平构建脑转移的风险分层,有助于预测HER-2低表达非Ⅳ期乳腺癌患者系统治疗后脑转移风险,以便准确识别高复发风险患者,对其制定有针对性的随访策略。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang X, Liu QY, Du HL, et al. [Risk stratification assessment of brain metastasis in newly diagnosed non-stage IV breast cancer patients with HER-2-low expression following systemic therapy]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42331553. doi:10.3760/cma.j.cn112152-20250418-00174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。